Audentes Therapeutics Inc (BOLD) Holdings Raised by Citadel Advisors LLC

Citadel Advisors LLC raised its holdings in Audentes Therapeutics Inc (NASDAQ:BOLD) by 981.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 110,921 shares of the biotechnology company’s stock after acquiring an additional 100,663 shares during the quarter. Citadel Advisors LLC owned 0.40% of Audentes Therapeutics worth $3,107,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Audentes Therapeutics in the third quarter valued at $143,000. Nationwide Fund Advisors lifted its holdings in Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares during the period. Trexquant Investment LP acquired a new position in shares of Audentes Therapeutics during the 3rd quarter worth $295,000. State of Wisconsin Investment Board acquired a new position in shares of Audentes Therapeutics during the 2nd quarter worth $210,000. Finally, Rhumbline Advisers acquired a new position in shares of Audentes Therapeutics during the 2nd quarter worth $252,000. 78.99% of the stock is owned by institutional investors.

Several research analysts have recently issued reports on the company. Bank of America reaffirmed a “buy” rating and set a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Evercore ISI assumed coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $23.00 price target for the company. Zacks Investment Research downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Raymond James Financial assumed coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $27.17.

In related news, SVP David Nagler sold 3,750 shares of Audentes Therapeutics stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $30.00, for a total transaction of $112,500.00. Following the completion of the sale, the senior vice president now owns 3,750 shares in the company, valued at approximately $112,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Orbimed Advisors Llc sold 672,000 shares of Audentes Therapeutics stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $28.25, for a total value of $18,984,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 758,500 shares of company stock valued at $21,340,610. 47.30% of the stock is currently owned by company insiders.

Audentes Therapeutics Inc (NASDAQ BOLD) opened at $28.38 on Friday. Audentes Therapeutics Inc has a one year low of $13.90 and a one year high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.88). equities analysts predict that Audentes Therapeutics Inc will post -3.52 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2017/12/03/audentes-therapeutics-inc-bold-holdings-raised-by-citadel-advisors-llc.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

What are top analysts saying about Audentes Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit